Porous matrix

• US 10,232,087 B2
• Filed: 03/29/2004
• Issued: 03/19/2019
• Est. Priority Date: 03/27/2003
• Status: Active Grant

• Current Assignee: Locate Therapeutics Limited
• Original Assignee: Locate Therapeutics Limited
• Inventors: France, Richard Melville, Quirk, Robin Andrew
• Primary Examiner(s): Yamasaki, Robert J
• Application Number:
  US10/550,151
• Publication Number:
  US 20060263335A1
• Time in Patent Office: 5,468 Days
• Field of Search: None
• CPC Class Codes: A61L 2300/254 Enzymes, proenzymes
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/43 Hormones, e.g. dexamethasone
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.

Claims

1. A porous polymeric composition in particulate or powder form, comprising:

a first phase comprising a first polymer and a plasticizer selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, polycaprolactone, low molecular weight oligomers of polyethylene glycol (PEG), polypropylene glycol, or polycaprolactone, adipates, phosphates, phthalates, sabacates, azelates, citrates, poly lactides, and poly lactide-co-glycolide;

a second phase comprising a second polymer,

wherein either the first or the second phase has a glass transition temperature of <

45°

C.,

wherein the composition forms a porous matrix when the phase having a glass transition temperature of <

45°

C. is heated to a temperature above its glass transition temperature above and mixed with the other phase,

wherein the first and the second polymers are selected from the group consisting of poly([a]-hydroxyacids), polylactic or polyglycolic acids, poly-lactide poly-glycolide copolymers, poly-lactide polyethylene glycol (PEG) copolymers, polyesters, poly ([epsilon]-caprolactone), poly (3-hydroxy-butyrate), poly (s-caproic acid), poly (p-dioxanone), poly (propylene fumarate), poly (ortho esters), polyol/diketene acetals addition polymers, polyanhydrides, poly (sebacic anhydride) PSA), poly(carboxybiscarboxyphenoxyphenoxy hexane) (PCPP), poly rbis (p-carboxyphenoxy) methanel (PCPM), copolymers of SA, CPP and CPM poly (amino acids), poly (pseudo amino acids), polyphosphazenes, derivatives of poly [(dichloro) phosphazene], poly [(organo) phosphazenes] polymers, polyphosphates, polyethylene glycol polypropylene block copolymers, natural polymers, silk, elastin, chitin, chitosan, fibrin, fibrinogen, polysaccharides (including pectins), alginates, collagen, poly (amino acids), peptides, polypeptides, proteins, co-polymers prepared from the monomers of these polymers, or mixtures thereof.

2. The composition according to claim 1, wherein the mixture of the first and second phase is porous and further incorporates cells from a target tissue site.

3. The composition according to claim 1, wherein the second phase is porous.

4. The composition according to claim 3, wherein the second phase has a porosity of from 10% to 97%.

5. The composition according to claim 1, wherein each polymer is biodegradable.

6. The composition according to claim 1, wherein the second phase is porous and further incorporates cells therein from a target tissue site.

7. The composition according to claim 1, further comprising cells.

8. The composition according to claim 1, further comprising one or more factors useful for promotion of tissue growth and development.

9. The composition according to claim 1, wherein the first and the second phase each further comprises drugs, hormones, enzymes, antibiotics, or nutrients, or mixtures thereof.

10. The composition according to claim 9,

wherein drugs, hormones, enzymes, antibiotics, or nutrients, or mixtures thereof that are comprised within the first phase are different than those comprised within the second phase.

11. The composition of claim 1, wherein the first polymer is the same as the second polymer.